Related Experiment Videos
Corticosteroid response in chronic lung disease of prematurity
Insights
Corticosteroids may improve lung function in premature infants with chronic lung disease. Infants responding to treatment had better outcomes, but more research is needed.
Area of Science:
- Neonatology
- Pediatric Pulmonology
- Pharmacology
Background:
- Chronic lung disease (CLD) is a significant complication in premature infants.
- Current treatments for CLD in prematurity have limitations.
- Corticosteroids are potent anti-inflammatory agents with potential therapeutic applications.
Purpose of the Study:
- To evaluate the therapeutic effect of corticosteroids on lung function in premature infants with stable CLD.
- To identify predictors of corticosteroid response in this population.
- To explore the potential of corticosteroid responsiveness as a prognostic marker.
Main Methods:
- Retrospective review of medical records for 23 infants with CLD of prematurity.
- Analysis of lung function parameters (AaPO2, PaCO2) before and after corticosteroid treatment.
- Comparison of clinical characteristics between corticosteroid responders and non-responders.
Main Results:
- 56.5% of infants showed significant improvement in lung function, indicated by decreased AaPO2 and PaCO2.
- These improvements were long-lasting.
- Responders had lower gestational age, birthweight, and less weight loss, with fewer days on oxygen.
Conclusions:
- Corticosteroids may offer therapeutic benefits for select premature infants with CLD.
- Corticosteroid responsiveness might distinguish CLD subtypes with better prognoses.
- Controlled clinical trials are essential to confirm efficacy and guide treatment recommendations.
Abstract:
The medical records of 23 infants with stable chronic lung diseases of prematurity who were treated with corticosteroids during the second month of life were reviewed. Thirteen (56.5%) had significant improvement in lung function as evidenced by a mean decrease in delta AaPO2 of 49.5% and a mean decrease in PaCO2 of 15.4%. These proved to be long-lasting effects. Infants who responded to corticosteroids had significantly lower mean gestational age, birthweight, and percent loss of birthweight when compared with the infants who did not improve with this treatment. In addition, the number of days they required supplemental oxygen were fewer. Thus, corticosteroids may be beneficial therapeutically for some premature infants with chronic lung disease. Alternatively, corticosteroid responsiveness may differentiate types of chronic lung disease with improved prognoses. Controlled clinical trials are necessary before corticosteroids can be recommended in treating or evaluating chronic lung disease of prematurity.